Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Patients With Von Willebrand Disease

Trial Profile

Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Patients With Von Willebrand Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Factor VIII/von Willebrand factor (Primary)
  • Indications Von Willebrand disease
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Grifols
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Apr 2020.
    • 06 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2020.
    • 24 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top